Diabetes Research

Approximately 30M Americans have diabetes. In North Carolina about 1M have been diagnosed with 2.5M in the prediabetes stage. With such alarming numbers it is not only important to treat but to also prevent. We are increasing awareness and emphasizing the importance of lifestyle management within our community while supporting our Biopharmaceutical Partners with industry leading Patient recruitment and study conduct services in support of promising new therapies.

EXPERIENCE

30% of overall clinical trial experience involves Diabetic Patients
Extensive Clinical Pharmacology and POC study experience
PK/PD, SAD/MAD, DDI, Food Effect and Adaptive Designs
Efficacy, Safety and Tolerability
Wide range of ROA capabilities

TECHNICAL SPECIALTIES

Ideal operational structure for lengthy confinement and outpatient designs
Dedicated rooms for specialized procedures
Strategic alliances for Metabolomics, Biomarker and Clinical Endpoint Assays
OGTT: Oral Glucose Tolerance Test with indirect calorimetry

DATABASE SNAPSHOT

CASE STUDIES

Comparing Single Doses Of 3 Modified Release Formulations with Immediate Release Material-Sparing-Tablet (IR MST) Formulation in Adults With T2DM

A Phase 1 Single/Multiple Dose Study Assessing Safety, Tolerability And Pharmacokinetics In Patients With T2DM

Study Of Two Dosing Regimens Compared To An Approved Agent (Sitagliptin) In Patients With T2DM

Phase 1 Safety and Tolerability Study in Patients with T2DM

Phase 2 Safety, Tolerability, PK and PD Study of an Oral Monotherapy To Treat Adults With T2DM

FAVORABLE DEMOGRAPHICS

WANT TO TALK ABOUT YOUR UPCOMING STUDY?